Medindia

X

FDA MEDIA ADVISORY - Briefing on ESAs Safety Information

Wednesday, February 17, 2010 General News J E 4
Advertisement


** CREDENTIALED PRESS ONLY **

WHAT:

A briefing on a new risk management program for erythropoiesis-stimulating agents (ESAs), which are used to treat anemia in certain patients

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO )

WHO:

-- Richard Pazdur, M.D., director, Office of Oncology Drug Products, Center for Drug Evaluation and Research (CDER), FDA

-- Patricia Keegan, M.D., director, Division of Biologic Oncology Products, CDER, FDA

-- Dwaine Rieves, M.D., director, Division of Medical Imaging and Hematology Products, CDER, FDA

-- Jeff Summers, M.D., deputy director for safety, Division of Biologic Oncology Products, CDER, FDA

WHEN:

Tue., Feb. 16, 2010, 1:00 p.m. EST

HOW:

Reporters may participate in a listen-only mode by dialing 888-995-9712 or for international reporters, 1-630-395-0260. The password for all callers is "FDA." A replay of the briefing will be available until Feb. 23 by calling 800-391-9845 or for international reporters, 1-203-369-3267.

CONTACT: Karen Riley, +1-301-796-4674, karen.riley@fda.hhs.gov, or Erica Jefferson, +1-301-796-4988, erica.jefferson@fda.hhs.gov, both of the U.S. Food and Drug Administration

/PRNewswire-USNewswire -- Feb. 16/

SOURCE U.S. Food and Drug Administration
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Aurora Health Care Selects Peminic Patient Safety ...
S
Radio Campaign Tells Senators Dorgan and Conrad an...